ACOR - Earnings call transcript Q2 2019 | Acorda Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Acorda Therapeutics' Second Quarter 2019 Update. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being taped at the company’s request.

I will now introduce your host for today's call, Felicia Vonella, Vice President of Investor Relations at Acorda. ahead. go Please

Felicia Vonella

Good Chris. Thank morning you, everyone.

and begin, that all we found our are remind those to disclosures you presentation will in public which filings, me our SEC encourage contain filings. be you check Before can let we forward-looking Detailed statements.

now Ron? the Ron pass will over to I CEO, our call Cohen.

Ron Cohen

it we We the that additional our everyone. fourth case. we're seeing and And believed would the afternoon, Good progress quarters or efforts Felicia. quarter quarter gaining made substantial quarter on signs of launch. second two that to the take three a of into this said the would sense the Thanks remains We the year strong of INBRIJA we before trajectory are traction. launch this last have during encouraging

of I'm products one space gate. our and INBRIJA vast the access are gaining Express major contract of see is in $X pleased we Today, that quarter this driver access. we're in completed the revenue formulary not key Scripts increases new we out for where to with of majority beginning of environment this report to reported A first million. launch covering this the payers already in an net And

by In Committee positive of Lauren analysis We future. a that Sabella, also Use and in our Commission. players launch. for INBRIJA CHMP Human and major status late Commercial do for regional so additional the recommending we Products or details near we additional several opinion European the with Chief comments we're approval Medicinal announced July, will opening plans achieved formulary that EMA’s the with issued expect with to payers my follow going -- the Officer major

to now opportunities and Europe. for currently EC’s on partnering will We're evaluating the the marketing forward final to And Europe. its EC in commercialize authorization decision we later decision year. opinion look consider this The INBRIJA in granting CHMP’s INBRIJA

pleased been million. erosion AMPYRA will That have revenue higher net over Lauren. revenue AMPYRA quarter over and pass I'll that than revenue be call remained of now projections $XXX AMPYRA, continued Lauren? the our XXXX We've we AMPYRA than second reported the to expect internal of million. branded do greater Moving to $XX sales expect time. we said we

Lauren Sabella

Thanks INBRIJA. everyone. prescription and cartons of were been received over Through Ron than afternoon XXXX number and forms total their greater good have XXXX patients prescriptions. requests than July, have XXXX, XXXX prescribed The received physicians more first have dispensed

prescribing mentioned of XX% specialists our from A During disorder first we Since call see within prescribing the the then largest of doctors number movement April, and in neurologists high Segment the these of segment importance physicians. seen includes the who all quarter which XX% increased we've to patients.

Segment of progress importance discuss more coming A in Additionally this these the slide. patient. for detail than of physicians more one the I'll have approximately XX% prescribed in

last as main also to to of We lever emphasized the quarter drive a need gain INBRIJA. insurance prescribing access the

improving National As formularies Ron commercial Access INBRIJA non-preferred for plan also for performance Part Medicare Express on and high added key their regional the on preferred with pointed Several status the Preferred Scripts accounts national and became basic INBRIJA. disease. Members Parkinson's have D also out

of With need exception of these lives. the medical for INBRIJA without Medicare is approximately and a available formulary for commercial wins XX% XX% now plan

to nationwide. for stage we've In expect have formulary This do We pilot from our have physicians future. one-month all to key we program trial addition in is trial June payers free placement are that to insured late and near other a to patients in commercially program also spent with the the in free discussions offices. agreements distributed samples additional

benefit actually feedback. patients physicians INBRIJA, experience from more increased will as the that expect We

INBRIJA processes. mind that We're and keep value important care will During different to reflected coverage. from XX in as improved coverage therapies prescription our their vary decrease due is for time demand depending managed five days to unlike of patients insurance continuous XX time distance needs. will most the frequencies to working to HUB average It this the use be from expanded other we the to on on quarter, an in prescriptions we improvement also boxes further reduced different gain per is This use, individual one as product can at therefore month. in

a market with Parkinson's OFF is about for reminder, addressable people that the total As have periods XXX,XXX.

to XXX,XXX more primary approximately The on OFF based represents three day. OFFburden market this experienced moderate the OFF one four day represents analyzed experienced or XXX,XXX and per patients per burden periods further to the research periods or segment OFF OFF low segments, per different characterize experienced three approximately and two who have patients segment We who secondary fewer XX,XXX patients approximately segment burden high day. OFF who periods represents

the important by dictated as This is for period will INBRIJA OFF person be experiences. utilization each burden

these into On the we share following our segments. data how slide, currently fits will

the consists the INBRIJA We’re who in was on This a value of cohort of represents March here often lowest in they July. shaded which dispense have INBRIJA on low help first how of been on and have that’s received through refilled first give slide to prescriptions forecast grey your their this by you based burden the that The month underlying in sharing models. utilizes prescriptions of a to utilization graph was utilization data perspective with reported was XX to since this date available March. the tracked you the patients segment patients their channel. is drug The whose

dispensed. XX% blue prescription. represents green shaded and that of of segment approximately of XX% see This approximately approximately prescriptions dispense dispensed. patients here about have XX% high approximately shaded The but cartons with the XX% represents who that the received cartons burden in all segments represents only you of XX% segments been the moderate of patients burden The comprises patients only in

utilization patients cohorts segment April has comprise of However all three July. XX% been across In which May between cohorts. added consistent and graph, the this the and XXX cartons it's we approximately dispensed that and Note March by XXX next the respectively.

doses segment between day per to and three are patients High low than to patients segment day, dose one and doses day. estimated per one two moderate use per four less patients

launch in INBRIJA patients that be early about segment. suggests burden utilizations So will half the by in driven summary, data of high

are a long-term by among this reminder, As specialists seen This movement within a for segment prescribing catalyst primarily and value. specialists. disorder segment increased as these seen patients growth we INBRIJA’s will have serve significantly and major

launch As will we additional one quarters we establish or noted expect our its April the in to require two trajectory. call,

encouraged disease. prescribers fulfillment the research progress of by care INBRIJA become continued will These well the consistent optimizing as reimbursement in to as and with conviction turn Ron. all patients. a market are supports back process We now our are positive in the made I'll we've which call our from both over of Parkinson's and in that standard feedback

Ron Cohen

Thanks Lauren.

table Moving XXXX, financials. to the second the quarter financial this outlines summary key of for the

the cash was balance at end the equivalents million. cash of $XXX Our and quarter

We can capital continue become additional long-term based without our to that believe we projections. positive on cash flow raising

for focus of remainder the our XXXX beyond. and highlighting So

the us that we're made and and year and continuing trajectory INBRIJA’s EC’s collaborations upswing both our to from decision with to in looking of can may in foremost INBRIJA, be appropriately we're the quarter a people puts progress so by we of commercialization Parkinson's year. now on an the between We will to so. and many First ensure benefit the end on in that believe the With with successful do the recent opinion forward positive ex-U.S. potential the of end as Europe second who the MAA, partners for discuss track CHMP on launch Japan.

and now The has additional to provided approval the develop applying uses. we're ARCUS that platform platform of INBRIJA validation therapies technology for of

Our deploying program resources Operator, on our finally And we'll to migraine. expenses take and advanced least is acute we'll maximize of shareholder most maintain controlling now questions. for treatment focus not value.

Operator

Instructions] first Kasimov [Operator with JPMorgan. from comes Cory Your question

open. line Your is

Unidentified Analyst

thanks for for This guys. my taking is Matthew Hey question. on and Cory

just my has can scripts? program help us you so conversion to the impact far been rate wondering first understand one better understand free trial of to what that So the paid and if

Ron Cohen

let I’m Lauren going that. to take

Lauren Sabella

Yes, hi.

the of rolled trial So we the nationally free June. at end right just now program out

started from we free program this have to really in don't to prescription. you paid share a it's point with really so that So any information trial regarding rates conversion and only at time the

Unidentified Analyst

trend wait then tend if to first docs and going more but of curious I think a my you've from before new one similar seen how their to you're I state prescribe guess before a and the talked it we've are long just about the or offering And they I'm if Tell a this two where last waiting two in prescribe it. me few question docs a patients? few or Got seeing drug. patients other beyond so launches one months before broadly.

Lauren Sabella

seen. also a that very point one interesting have it's we and Yes,

didn't we been the which that that and access a created to to docs, matter we to tell highest the physicians physicians as have prescribe than in they So I've that product. fully opens have upfront write until adopters start seen that's waiting early that the field, that also can there even I've that been out for is dynamic anticipate before are in there's you I been XX% of telling is going those physicians a that more. talking high there to them prescribed patient. segment now prescribed they're one and out are more those XX% prescribed have of have about And of us those of fact actually

in be get product position the of a it's to value burden to a see want to where don't patients but So they drug. heavy the they

waiting they So up open their open they prescribing. before the to are for access

have agree we seen. So with what you

Unidentified Analyst

thanks question. for taking Awesome, my

Operator

is question Stifel. with next from Your Paul Matteis

Your is open. line

Paul Matteis

I you early you if your terms reimbursement, market Part being Part are little you color how refill taking for and rate could D? but to the much reimbursed. and give maybe much. so so going ultimately then adopters to seeing of Thanks questions. Great. Thanks wondering you're be how I it's in What is more are among could a seeing was today more on much what scripts of think bit know you early speak D do the the channel in segment through what target

Lauren Sabella

to between even being a term and what's split with the terms being both patients both that that And first the the the we're of question last that's in filled. written So is now start I'm in what's right and patients. and and Medicare commercial prescriptions going of in seeing terms is pretty

now are D a approximately commercial insured XX% of right So lives. the that's of for XX% only commercially Part where bit now right lives that's in is unencumbered access Medicare are space while we easier Access currently.

expect of and the that. the the Medicare just access even restrictions dispensed those Part in we better access over That question? D. said It's as I've phase. we'll first have And your the PRFs XX% Part D said in in you repeat XX% space. launch are being of with expected We time early prescriptions that Medicare Could

Paul Matteis

I Again to of the you it's rates. expectations? I'm refill tracking now least the comment starts rates early earlier but at know how on maybe refill your Absolutely. and relative you're timeframe and some what curious seeing with could are from March

Ron Cohen

that. Yes, is essentially, market in Paul in what depends too presentation the Ron. on really Lauren take who's where that's we prescriptions this the and it comment It's on getting what early because with showed of I'll rates them and really right. refill showed, it's this the to segmentation

OFF So or you're XX% the burden dispensed. if that are you're in its of scripts, of for that boxes upper accounting XX% XX% being disease of burden,

months. that are too we get then And physician prescription five all. month boxes prescriptions. one, where of this words when refilling And really physician that working boxes behavior. is what that broad dynamic can't being a patient other respect with months market how the two mean it's one used to four, And early and and the two, as look to to fits across or over three prescribes, then versus range in three how does over point of by that pretty in was tell you versus is a that for was many those given wanted variety or It's prescribing a at

or top really percent more. worth those times, It if five that is that what are is not XX% lower four the

it. in confidence over now all more to numbers tracking importantly that be present of time, refill able still and time, But get more we more we actually that get we're so too the and to really to some it's early on rates that. going we're as more comment So right

Paul Matteis

Ron. how the chunk towards the a surprised launches you, I like if quick more follow-up just aren't greater spectrum. you drug adopters on could your of the of go? It end are Thank one ask that's comments, of usually seems severe that Ron early one most

Ron Cohen

Yes certainly.

we're number So actually it And I've really see is of we're talked to on pleased the as docs. what the and the quite talking the well point a it’s been doctor that here to range. right. and depends out you're I've rides across to on

absolutely who have earlier out blank, better even them. they'll are they be that mold could a So think where it's when told doctors for I there's working severe. start in and are even other and patients off, are There point more more with some this who who have doctors active me my to stage an disruptive actually

So we're more continue progresses people going as this get feel more a launch we and get to to of on drug. the

say that reality So not wouldn't it. surprised I I'm that yes, the of

that still there sometimes that week exactly course the and surprised because can they few terrible periods see of way we've and OFF they're that, all where who very it early for pleasantly of one is we the employment is depending but I'm activities quite them and kinds be even always active Parkinson's someone disease the docs younger life and that it awful including in on are do relatively burden happens when. a that their seen have is still way has in it

a who of so can talked potentially recognize surprise that everyone me, these will INBRIJA if OFF upfront. quite the it's number to And use has I've is docs help a periods that there offer to and the that

Lauren Sabella

just can penetrate often that's however that mean higher and into those would movement have of something to patients number be of more in physicians I that. just XX,XXX I if are more patients. see, of And of segment things the the see do they patients one targeting calls patients. largest deeply the in of of And virtue disorder terms they to add Right. season who that that doctors more of would severe number the by very a proportion we

math, would volume those would that higher would product, physicians that when and be patients when the really of time a the severe. over start and So you you there board getting they start you kind on do just adopting of more be writing their anticipate

Ron Cohen

that’s absolutely right. Right,

Paul Matteis

the Thanks. it. Yes, got it. details. Thanks Appreciate much for so

Operator

Salveen Richter Sachs. next is Your from question with Goldman

is open. line Your

Salveen Richter

and Thanks my with for comment on to access additional gating here rate which access regard questions. come on at the you to Can board? factors just taking formulary expect the you get to

Lauren Sabella

is mentioned, Well which we the had that we really large had hi. the with win we regional and also first are Yes, some we've SI wins. pleased significant as

the large fill Veterans means not available out of form Parkinson's without available We Administration do have formulary, although ability patients also the they that on has a an the it's which that is drug not to but exception number in an and have criteria it's arduous process.

on So this point. board we have at that

which in We are payers patients very will close than having of very to tip access the scales terms several not. other more large with

right anticipated what So care we access the launch. managed terms little track actually and on of in we of early a in are ahead this

Salveen Richter

And just here. a follow-up

access understand do XXXX talked high get that, to maybe about You've the to past target in target How guess the prescribers. help that volume you, just us hitting time I group? period the

Lauren Sabella

getting. pleased we're we're with So where

XXXX of XXXX the really And important than currently group physicians. and XX% for written for them products physicians of that the again, have for are product that to that more So patient. it’s written one XX% XXXX really about have so are

opens. talked get some that do prescribing lot about So to we group us still are get because have those waiting just do of physicians have also access the to They're another we opportunity work but a the start XX% the to that gives physicians these of until next and we more to earlier.

we most So are reach that's of where the those of physician. important in terms

Ron Cohen

managed issues a of which is get that and that last care off anticipating you address means I'll to to few was on there's we And that what table. a quarters. where process said quarter Right. prescribing going with formulary and our have the the involved add get just beginning burden the This we it call take were

safe the back it's So don't they to for But have have that them and peers doing with the those get undue you and and all number safe were get then then be to and don't have few to and back on come come patients with you takes office they're right. peers to water, medical then because And give burden off on the start experience prescribe reports exceptions, positive fact that to it office. feedback being months one a which now you as two going not they an back which that not the go to you positive the understand the physicians overburdened to get it's it's in in go is to exceptions loops once right medical them INBRIJA. table, their

more there's to Now where encouraged more they loop patients. and a are for feedback their of prescribe positive

recognize time, to the it was the just surprising have they gate, space out said care really a other the it’s out you going in thing that cycle. The rolling they're to but of address wait least as the burden a prescribers to that because than to process takes somewhat just managed the wait all for upfront. degree Lauren the and and steps to issues was out that to in We expected which they of wait, that decide of they're the just us going this know been at the be So only conditioned we in wait going to it's terms process. right way, it's

Lauren Sabella

physicians up to we thing. just had pen the other quarter, paper first add put of that I'll In now XX% had XX%. and one those to And mentioned top we're

even So for we to though they're access, are they're starting away waiting chipping write.

metric So very, very it's watch that important carefully. we

Salveen Richter

you. Thank

Operator

with Cowen Company. next and question Your Phil from is Nadeau

line open. Your is

Phil Nadeau

taking for afternoon, Good my thanks questions.

answer First prior an to insurance question. the access the in

segment be year? today by patients you of where that of than that the access give do of end XX% what quantification the could some you have Could think covered high suggested us lives and less access have insurance today. it's the You proportion of

Lauren Sabella

works get way. doesn't it's of get based that basically that that how it this is you access, The insured plan determination. by that formulary Yes, you and then make way the lives segmented number on unfortunately

get that covered. don't to of level have ability terms of So into an we lives segmentation in

Phil Nadeau

much is for proportion lives How generally access? of covered

Ron Cohen

in way access on it's to now. some lives believe and major now up that XX% future. about for Just making with significant commercial that's payers there reminder, good the have Part be discussions by the near open remaining of having future on about near we based of the we're the going the will of inroads We Medicare in XX% we D

Phil Nadeau

that’s Perfect, drug free what's samples. free of give how that differ does trial free helpful. from And program on duration the And the the patients? free the both program, that product INBRIJA the

Lauren Sabella

Okay.

So actually the is is directly that XX to doses a sample sample shipped physicians gets per office and program carton. the that

the the or to physician And the that having we OFF one inhaler the think on been hearing we've and And some they've that office the state to and is of training them the come heard drug the sample give quite actual the administering is actually stories physician the on an and things right opportunity patient has they're out in is fantastic then in that so them have remarkable. actually there. we're watching the and patient after the of the trained patients INBRIJA of they're impact

been really that's to hear. exciting So

checks in doses, INBRIJA. the dose different in that from a XX is the space that has as out capsule the check the data, be carton that's if now the and What is a out, in on So patients counted the the program. the trial done XX able he fill of Medicare pharmacy excuse box a type he to IQVIA it's What they box to I'm rolled sorry XX insurance not same the carton their is issue XX D with all again gets one partly this doctor’s an specialty filling we've patient -- the time XX commercial that's is of Part the to to also mitigate we've as And is dose, do process prescriptions prescription this a place. me free of allowed to the hand carton, for because form while have taking ability only sample. not

the to drug days like and So about give them and patient they within an XX before the talk days training they though the a drug, makes we they has patient videos the additional with of can versus wait the difference them doctors about issue. they a them the that the the information they patient talk gets couple they get train the if et be to medication, patients, When big even to cetera. this because think train it drug,

this we the to shorten physician beyond But program fill. augment even ability patient, out to the time So free trial to that, medication. trial the the given for we've

Ron Cohen

to that we And Right. make re-emphasize. just sure

a to which whittle down XX started day expect XX point we even we're We've we days we day, with with AMPYRA. gotten pretty XX to down much further process. going So at out it this that and what did is

Phil Nadeau

taking That's my very Thanks for helpful. Perfect. questions.

Operator

Michael Your with next question is from Yee Jefferies.

open. line is Your

Michael Yee

you thanks you third-party I whether guys, on regarding sales interpretation your guess to Two question. is progress. Congrats the versus it's the and talk what data or one guess accurate. not reported is Hey for of can showing fairly clarity convert questions think any to the trying I

a think made any then before that follow-up. you've to gross what at? maybe and a related And on about that looking you I think is net estimate I had to Ron comment

Lauren Sabella

data pretty internal to for that more much is over is right tracking board come VA, can to our So discussing such internal is change now, our I may as But that for in very IQVIA it's gross right on time we're now metrics. the tell line INBRIJA numbers. not may channels you with change closely what dynamic. net, as What

Michael Yee

around step for separate much that confidence make then to through we think are plans all finance a capital your questions at which Ron, model no Okay, think that the that's a non-dilutive can regarding sheet capital the take sense to I'm I questions other that the which I what given and sure certainly and you questions getting debt. structure relate through equity is confident you extent comment current much. need think raise of I you and all capital certainly And helpful. but level or Can where so these capital if markets. and burn more markets balance or a a Thanks all you to cash I picture feel think stock need the get from to other you're bigger to Ron financing? back, And launch prices question no and I of lot that to there's forms as of out think

Ron Cohen

yes we $XXX due debt So I have million the in believe of convertible debt, June XXXX. that's

can is INBRIJA maintain than need doing we on get cash it's order can a AMPYRA to cash to flow already INBRIJA. launch So years We're based for to I We mentioned keeping INBRIJA, stages every cash, making due it's presentation eye that to course. more can based our and which even the two making certain about that do not for thought. we on the would on flow and we're positivity had and for in always obviously believe it a positive the With where expenses. those are now. going aware in from that to projections of better raise as we or extent that well And inflection cash in we we we're to go projections believe sure to flow dollar address and in and planning long-term address very that point obviously various that we get on close ways that we count. so and will cash but respect we We to

Michael Yee

Okay.

That a in certainly better. how for swing about doing a one was is but you comment AMPYRA definitely last sorry the factor And huge quarter. follow-up the made positive

still there despite of that there, what? in that's but on So mean to is I think actually up not anything or I are say surprised great. quarter-over-quarter, the there what I'm as it we're mean going generics, many something just happened to is well is pleasantly I sales is so appreciating model that

Ron Cohen

comment or on you’re not. what can't appreciating I

about very to the cared good that we would as brand AMPYRA doing or as say that loyalty I things years that to believe entire that the product I residual brand And we degree building it that we're benefiting of value. from high INBRIJA the boil an down, patient, marketed people we went if for cared about selling community I launching on process we maintaining and the supported trust from the that, Our there and think ongoing was brand through had patients. for community, spent is view me patients way. a to it the and we excuse a to And came I is we that good number and

Michael Yee

Thanks Okay. so much.

Operator

Your next Charles question Duncan from Cantor. is with

is line open. Your

Charles Duncan

continuing Hi and for this congrats probably on impact question issues. of to seem the seasonality in wondering over the taking seeing a traction you're of guys. the that access versus thoughts companies wondering may heard regarding be formulary early course Lauren Had of albeit your of counter the for rest impact their traction what year? year Thanks some and the the are INBRIJA. if we've that with quick a on kind of prevailing get to those I'm those yet bit two things of question the you're be little about and considering

Ron Cohen

you crosscurrents what clarify seasonality you what? just can Hey little Charles, mean with versus by the a bit

Charles Duncan

of would seem trigger cetera, and because to relative formulary that are quarter access? people that mean more prescribing would access impacts positive I seasonality additions. access on a going the those third being formulary be With vacations big to et but for

Lauren Sabella

when any hard major impact launch care again wins seasonality this Yes, place to now. managed in it's and a getting there's we're early perspective from trajectory just whether in determine you're a the really

the quarter more uptick formularies in the be of would brand. say and think that see I say, we hard we will in to trajectory that have will So managed the place should an we care I fourth do that anticipate

Ron Cohen

go It's too prior because our months do across early a and and I Yes on agree slack to have just obviously based on product on tend particular and go say patients I’ll summer things. phase. categories, observations them we're add, us among vacations to in this because other this for in some doctors launch the experience vacations and launch for

you which and in been drug establish I we season way. more or over AMPYRA informed talking pattern could about for season were there comment think AMPYRA, that if another did with years a had few could we more out year-over-year we a a

But getting has the months. on a crosscurrents of it's influence you much scenario, It do summer going have all an formularies. is We or launch, these how we know where in were a that not. launch don't

you're we Lauren I pointed get beyond. is out, the we is September say by of out into summer think can and the as what time which getting

way that of its through, work All will right.

so asking we'll won't be expect our more to going and the significantly be on question. we season, having to So be access we're formulary we that done way summer the with

Charles Duncan

more it'd Right. rethink. But vacation recharge they and be follow-up, Quick to that. and well. helpful sell-siders quick follow-up could Maybe on went if as investors

ex-U.S. that tango. launch I partners, would preference to it approval? versus anticipate to couple to would a me or prior after the of it you two and partners European you Japan efforts, partners your different think have partnering Regarding takes that excuse approval to or know about when be But prior

Ron Cohen

you about a or partners of separate talking partners EU the a Charles? Are EU, couple different couple for Japan of for and

Charles Duncan

the geographies. different Really two separate for

Ron Cohen

being placed it coming what to have the that's see and from what and it. Yes, the is is market on and what explore where you the interest the nature value of

across board. that that it. deal a versus and nothing that doing we being parties encompasses having wouldn't from there's separate So conversations I we If don't one that about that the we're we party, know doctrinaire both like two we're have says take

Charles Duncan

early Okay, on thanks Congrats progress. the color. added for the

Ron Cohen

Thanks.

Operator

with Selvaraju comes Wainwright question Co. from H.C. Raghuram & next Your

is line Your open.

Edward Marks

worked know had on I majority mentioned are any this dalfampridine, Good the buy you well on And is Ram. taking looking that call? And just that you're just whether you’ve I’m inventory then the through wondering questions. on how last forward, afternoon, at call the last at if looking generics Appreciate many the the you've now. market Edward purchased downs and of in mentioned your inventory, as going you previously for

Ron Cohen

to And so generic. I generics are and on with have believe four that there about Mylan, inventory? authorized you the authorized the It’s we five then the Dave market. right? that’s four Is want including talk total generic an

David Lawrence

sure. Yes,

we are the inventory. through working So

the through still last inventory was wouldn't expected. ordering holds we faster I and -- statement are but we anymore quarter think our going XXXX than that we in that be

Edward Marks

was then about, the least I currently physicians access lot a scientific follow-up patients? if using the know in your to And carbidopa/levodopa there's lot you're around there INBRIJA at whether a any these but excellent. you from concerns INBRIJA. be of just and headwind just early talked wondering would lot this to the accelerate waiting and on status responsive Okay, one in a seems perspective, this physicians non of to seeing build launch I that wondering on a timeline

Ron Cohen

paper to whole compresses time the one or in debunked been much papers after accelerates and another couple actually in This course the has there historical they that that up L-dopa brain it degeneration pretty in field that nail the thing. been and in coffin the a severity reasons since there a that is actually if has With accelerates it because back it grown L-dopa and you the dates So XXs. around of of myth, of has disease. said the chronically for put the a mythology the give that recently were the where

believe in that was all editorial JAMA I there that. summarized an

So it's definitively not just true.

there However and that who some in certain era who of who mythology up neurologists grew absorb that. retain that are

specialists that. for docs and at certainly So those fortunately disorder and the more sort movement of doctors the the as prone nearly of to the MD with are generations not recent

to when up education we the it, through it and encounter But papers the process. that go we we back we and have have scientific literature

the So and concerned it's that some way, and have get and as patients have heard absorbed by something about. well

it's minor It's -- call there's in a you theme. and and it. of educate through theme a you I launch the deal it that one with wouldn't the So major themes

Edward Marks

Perfect, my questions. Thanks taking details. for the appreciate all I

Operator

Your comes next from Olson Oppenheimer. with Jay question

Your line is open.

Unidentified Analyst

recent impacted INBRIJA Jay. events for as were for color such opportunity Matt view of market Thanks. of Appreciate maybe or NDA wondering We this if formulation for your recent there. the is the any filing on failure recent any Levodopa Neurocrine’s Hey Opicapone. XR

Ron Cohen

an and Those Yes, adjunct are no events patient it taking is that anything to chronic opportunity INBRIJA the not reason not an the related is that at is INBRIJA to as therapy. on-demand all. maintenance the for therapy, is

levodopa, and whether an then patients and up added course number them periods they're kind patients and will a having So carbidopa how other drug-drug COMT depending MAOI more drugs of mechanisms severe adverse additional and a the or sometimes so interactions dopamine to have with on many a taking three they are it's XX% wind with in on pharmacy. of compensate very events or wind sometimes or are The two, of some OFF associated of agonist. or effort different most drugs often taking up more with that and poly severity

to is very challenge, if including overdoing of day dyskinesia the disruptive. the extremely getting the of or most balance against can a effects it the physician be all control out side that giving which trying the the of So up motions you having you wind symptoms patient and are day involuntary frustrating increasingly

one whole think ideal the very you gut if nicely issues this this about actually because is for INBRIJA fits that situation. giving of drugs So an it is not through disease paradigm the major into

not It's great. The compromised. down, gut in absorption Parkinson's is slowed is

of gut susceptible is great L-dopa L-dopa time But together and in. very you the Some less and put through gets predictably. less it to gets they're the with yes a not are and absorbed itself disease, really drugs as it notably the so drug well you in go in effects, it when food all

drugs So candidates whatever is of any goes there for they're taking plus having there. or Opicapone INBRIJA the that are is periods, OFF are If L-dopa still it's that they other and or available. out Entacapone messaging that breakthrough the whether

Unidentified Analyst

great. device support be quick video, patient would of I instructional the one the so you seeing patients INBRIJA you. the any That's if some educational telling feedback much. anything you there would it. anecdotal then that on you're that And there's like that Got one user more mind thank helpful, Thank if just providing friendliness caregivers or you're may just really us

Ron Cohen

materials I’ll hit. start to rave and a the reviews providing as on I'll So that huge it well We're then getting Lauren. turn we the video are is

asked so get the when them, and Some a can prescription. in they them the of on him get so have and patients they all office for doctors have more

over we ask it. getting use many is user-friendliness to in many what the use going XXX of And friendliness, pretty we're hearing of because it. of significant plus, because dropped much dropped it of entire reminding the two, out the which not we're XXX clinical trials program how out out out two user or terms how patients In couldn't issues saw in they just the clinical they ability use with to couldn't trials

So that tracks the clinical trials.

In we're terms of to on repeat, we're anecdote, some stories about understanding from And hearing label. stay of this stories I anecdote, from they're anecdote it, coming really have can't Lauren? phenomenal some well nothing remarkable a the patients gratifying way from and hearing the them helped But that field I has. is how that has with in else

Lauren Sabella

back mentioned go what I'll the the office. that earlier, fact and had are Yes I samples in the to

doctors of hearing something are patient of sitting medications with from Some That's watching where their the market. just these there turn the that the don't we're in back most you actually and eyes. stories see they're on in front

So impact as that's having major a well.

Unidentified Analyst

Got it. for the you so much Thank time.

Operator

Q&A This period now to presenters for over back any concludes I'll for the things today's the call. remarks. closing turn

Ron Cohen

great updating we you for everyone you to Have and next thank All us weekend. look joining forward quarter. well a right,

Lauren Sabella

Thank you.

Operator

This concludes today's conference call.

now may You disconnect.

Acorda Therapeutics (ACORQ) 1 Aug 192019 Q2 Earnings call transcript